痛风或高尿血症患者的尿酸降低疗法的心血管结果:一个网络元分析
Yilong Yan1,2, Ying Bai1, Jiawei Wang1
1Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Expert opinion on drug safety
|November 14, 2024
概括
尿酸降低疗法 (ULT) 通常对痛风患者表现出良好的心血管安全性. 与febuxostat相比,Allopurinol降低了心律不整的风险,尽管整体差异并不显著.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 类风湿病学 类风湿病学
背景情况:
- 痛风和高尿血管理通常涉及尿酸降低疗法 (ULT).
- 评估各种ULT的心血管安全性对于患者护理至关重要.
- 对ULT进行比较的安全数据对于临床决策至关重要.
研究的目的:
- 评估和比较不同尿酸降低疗法 (ULT) 的心血管安全性.
- 分析与ULT相关的重大不良心血管事件 (MACE) 和死亡率的风险.
主要方法:
- 随机对照试验 (RCT) 报告心血管结果的系统审查和元分析.
- 进行了双对和网络元分析,以确定赔率比率 (OR) 和95%置信区间 (CI).
- 用累积排名曲线下的表面 (SUCRA) 来根据心血管安全性对ULT进行排名.
主要成果:
- 与费布斯塔特相比,阿洛普林醇显著降低了心律不整的风险 (OR 0.69-0.71).
- 在ULT之间或与安慰剂之间没有观察到其他心血管结果的统计学上显著差异.
- 费布克索斯塔特和佩格洛蒂克分别显示了缓解MACE和全因死亡率的最高概率.
结论:
- 总的来说,尿酸降低疗法在患有痛风或高尿血症的患者中显示出良好的心血管安全概况.
- 费布克索斯塔特可能与阿洛普林醇相比,具有更高的心律失常风险.
- 需要进一步的研究来验证这些比较性心血管安全研究结果.
更多相关视频
11:47Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
Published on: March 4, 2022
2.2K
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
1.9K
相关概念视频
01:16Antihypertensive Drugs: Action of Diuretics
623
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
623
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
538
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
538
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
495
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
495
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
481
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
481